SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • June 2nd, 2014 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Ohio
THIS SEPARATION AGREEMENT AND RELEASE (the “Agreement”) which becomes effective following the expiration of the revocation period set forth below in this Agreement, is entered into between Navidea Biopharmaceuticals, Inc., on behalf of itself and its partners, officers, employees and agents, the shareholders, directors, officers, employees and agents of its partners, and affiliated, predecessor, successor, and other related companies, and each of them, jointly and severally (herein singularly and collectively called “Navidea”), and Mark J. Pykett, V.M.D., Ph.D., on behalf of himself and his heirs, executors, guardians, administrators, successors, and assigns, and each of them, jointly and severally (herein singularly and collectively called “Executive”), who together are sometimes referred to herein as the “Parties” and who agree to be bound by all of the terms and conditions of this Agreement.
CONSULTING AGREEMENTConsulting Agreement • June 2nd, 2014 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Ohio
THIS CONSULTING AGREEMENT (“Agreement”) is made by and between Mark J. Pykett, V.M.D., Ph.D., an individual residing at 223A Main Street, Boxford, MA 01921 (“Consultant”), and Navidea Biopharmaceuticals, Inc., a Delaware corporation, with principal offices located at 5600 Blazer Parkway, Suite 200, Dublin, OH 43017-7550 (“Company”), who together are sometimes referred to herein as the “Parties.”
